TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies

Cancer Chemotherapy and Pharmacology

Volumn 80, Issue 2, 2017, Pages 261-273

  Burris, Howard A ^a,b   Kurkjian, C D ^a,c   Hart, L ^a,d   Pant, S ^a,c,f   Murphy, P B ^a,b   Jones, S F ^a   Neuwirth, R ^e   Patel, C G ^e   Zohren, F ^e   Infante, J R ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b Tennessee Oncology PLLC   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d Sarah Cannon Research Institute/Florida Cancer Specialists   (United States)

^e MILLENNIUM PHARMACEUTICALS INC   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Combination chemotherapy; MLN0128; Phase I; Solid tumors; TAK 228; TORC1 2 inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; SAPANISERTIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; BENZOXAZOLE DERIVATIVE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PYRIMIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BREAST CANCER; CANCER PATIENT; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FAILURE TO THRIVE; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SMALL CELL LUNG CANCER; SOLID MALIGNANT NEOPLASM; STOMATITIS; THROMBOCYTOPENIA; TRACHEA OBSTRUCTION; TREATMENT RESPONSE; VERY ELDERLY; VOMITING; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; MIDDLE AGED; NEOPLASMS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOXAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; NEOPLASMS; PACLITAXEL; PYRIMIDINES; TOR SERINE-THREONINE KINASES; TRASTUZUMAB; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85020636441     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-017-3343-4     Document Type: Article

References (50)

1. Dazert E, Hall MN (2011) mTOR signaling in disease. Curr Opin Cell Biol 23:744–755
2. Hsieh AC, Liu Y, Edlind MP et al (2012) The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485:55–61
3. Wu R, Hu TC, Rehemtulla A et al (2011) Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res 17:7359–7372
4. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12:21–35
5. Cantrell DA (2001) Phosphoinositide 3-kinase signalling pathways. J Cell Sci 114:1439–1445
6. Fresno Vara JA, Casado E, de Castro J et al (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30:193–204
7. Huang J, Manning BD (2009) A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 37:217–222
8. Pene F, Claessens YE, Muller O et al (2002) Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21:6587–6597
9. Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6:729–734
10. Liang J, Slingerland JM (2003) Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2:339–345
11. Benjamin D, Colombi M, Moroni C et al (2011) Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 10:868–880
12. Vu C, Fruman DA (2010) Target of rapamycin signaling in leukemia and lymphoma. Clin Cancer Res 16:5374–5380
13. Robb VA, Karbowniczek M, Klein-Szanto AJ et al (2007) Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 177(1):346–352
14. Dal CJ, Zancai P, Terrin L et al (2008) Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 111(10):5142–5151
15. Xiao L, Wang YC, Li WS et al (2009) The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res 28:152–158
16. Matsubara S, Ding Q, Miyazaki Y et al (2013) mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions. Sci Rep 3:3230
17. Mahadevan D, Chiorean EG, Harris WB et al (2012) Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer 48(18):3319–3327
18. Sarker D, Ang JE, Baird R et al (2015) First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res 21:77–86
19. Yang Q, Modi P, Newcomb T et al (2015) Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res 21:1537–1542
20. Agarwal R, Koenig K, Rohren E et al (2014) Combined antiangiogenic and mammalian target of rapamycin inhibitor targeted therapy in metaplastic breast cancer harboring a PIK3CA mutation. J Breast Cancer 17:287–290
21. Bellmunt J, Puente J, de Garcia MJ et al (2014) SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol 16:1043–1050
22. Signorovitch J, Swallow E, Kantor E et al (2013) Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison. Exp Hematol Oncol 2:32
23. Thoreen CC, Kang SA, Chang JW et al (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284:8023–8032
24. Wan X, Harkavy B, Shen N et al (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13):1932–1940
25. Carracedo A, Ma L, Teruya-Feldstein J et al (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118(9):3065–3074
26. Figlin RA, Kaufmann I, Brechbiel J (2013) Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. Int J Cancer 133(4):788–796
27. Carracedo A, Pandolfi PP (2008) The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27(41):5527–5541
28. Feldman ME, Apsel B, Uotila A et al (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7:e38
29. O’Reilly KE, Rojo F, She QB et al (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500–1508
30. Tabernero J, Rojo F, Calvo E et al (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603–1610
31. Korets SB, Musa F, Curtin J et al (2014) Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer. Gynecol Oncol 132(2):468–473
32. Zheng B, Mao JH, Qian L et al (2015) Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma. Cancer Lett 357(2):468–475
33. Ingels A, Zhao H, Thong AE et al (2014) Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. Int J Cancer 134:2322–2329
34. Gokmen-Polar Y, Liu Y, Toroni RA et al (2012) Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Breast Cancer Res Treat 136:673–682
35. Lou HZ, Weng XC, Pan HM et al (2014) The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells. Biochem Biophys Res Commun 450:973–978
36. Zhang H, Dou J, Yu Y et al (2015) mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis 20:50–62
37. Slotkin EK, Patwardhan PP, Vasudeva SD et al (2015) MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma. Mol Cancer Ther 14:395–406
38. Kannan K, Fabrey R, Cooper J et al (2013) MLN0128, an investigational mTORC1/2 inhibitor, demonstrates potent antitumor activity alone and in combination with paclitaxel in preclinical models of endometrial cancer. Mol Cancer Ther 12 (abstract B198)
39. Chiang CT, Yeh PY, Gao M et al (2010) Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma. Cancer Lett 298(2):195–203
40. Shafer A, Zhou C, Gehrig PA et al (2010) Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int J Cancer 126(5):1144–1154
41. Miller TW, Forbes JT, Shah C et al (2009) Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 15(23):7266–7276
42. Garcia-Garcia C, Ibrahim YH, Serra V et al (2012) Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 18:2603–2612
43. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
44. Ghobrial I et al (2016) MLN0128, an investigational oral dual TORC1/2 inhibitor: a phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström’s macroglobulinemia. Am J Hematol 91:400–405
45. Infante J, Tabernero J, Cervantes A et al (2013) A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies. Mol Cancer Ther 12 (abstract C252)
46. Shapiro GI, Rodon J, Bedell C et al (2014) Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 20(1):233–245
47. Rodon J, Dienstmann R, Serra V et al (2013) Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10(3):143–153
48. Infante J, Tabernero J, Burris H et al (2012) A phase I, open label, dose-escalation study of an oral mammalian target of rapamycin inhibitor INK128 administered once daily in patients with advanced malignancies. Cancer Res 72 (abstract 5588)
49. Tabernero J, Cervantes A, Gordon M et al (2012) A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies. Cancer Res 72 (abstract CT-02)
50. Xu R, Nakano K, Iwasaki H et al (2011) Dual blockade of phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer. Cancer Lett 306:151–160